Israel's Elscint, which is listed on the New York Stock Exchange, hasestablished a wholly-owned subsidiary, Elscint BioMedical, to focus on investments in early-stage biotechnology companies. Elscint will allocate $30 million for the subsidiary and a scientific advisory committee has been set up at the new unit.
EBM's first investment, made earlier this year, was in Gamida Cell, which develops proprietary technology for multiplying stem cells. The company also noted that, as part of its "quest to be a leader in the biotechnology sector," it expects to establish in the next year an international umbilical cord blood bank, which will provide a broad-based source of stem cells collected. Elscint's chief executive, Rachel Lavine, claimed that biotechnology is an exciting area of investment for the company as there are many Israeli firms that offer "opportunities with significant growth potential."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze